| Cameron, Donald W |
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study |
|
|
| Recruiting | 3 | 12000 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 09/26 | 09/26 | | |
| Recruiting | 2 | 10 | Canada | Vedolizumab (brand name Entyvio) | Ottawa Hospital Research Institute, CHEO Research Institute, Nebraska Centre for Substance Abuse Research | HIV-infection/AIDS | 12/23 | 12/23 | | |
| Cameron, Bill |
NCT04258475: The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. |
|
|
| Recruiting | 4 | 12 | Canada | Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily., RAL, Isentress®, Calcium carbonate antacid tablet, TUMS® Ultra Strength (US) 500 mg | Ottawa Hospital Research Institute | Calcium Supplementation in HIV Patients Using Raltegravir | 06/24 | 01/25 | | |
| Recruiting | 2 | 10 | Canada | Vedolizumab (brand name Entyvio) | Ottawa Hospital Research Institute, CHEO Research Institute, Nebraska Centre for Substance Abuse Research | HIV-infection/AIDS | 12/23 | 12/23 | | |
